Latest Tax Incentives News

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Cadoux Limited has made significant progress in its High Purity Alumina (HPA) front-end engineering design and advanced the Minhub rare earths feasibility study, positioning itself strongly in the evolving critical minerals market.

Hawsons Iron Limited reports solid progress on its Preliminary Feasibility Study for the Hawsons Iron Project, alongside promising metallurgical research with CSIRO and a successful $1.9 million capital raise.

Opthea has significantly reduced its operating costs and settled a key financial liability, positioning itself for a strategic review aimed at unlocking shareholder value.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Tennant Minerals has announced a maiden high-grade copper-gold resource at its Bluebird discovery, alongside new exploration targets identified through gravity data modelling. These developments set the stage for advancing project development and further drilling.